1. Home
  2. OKE vs ARGX Comparison

OKE vs ARGX Comparison

Compare OKE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ONEOK Inc.

OKE

ONEOK Inc.

N/A

Current Price

$85.71

Market Cap

53.3B

Sector

Utilities

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$731.49

Market Cap

52.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OKE
ARGX
Founded
1906
2008
Country
United States
Netherlands
Employees
6326
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.3B
52.0B
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
OKE
ARGX
Price
$85.71
$731.49
Analyst Decision
Buy
Strong Buy
Analyst Count
15
19
Target Price
$89.27
$991.56
AVG Volume (30 Days)
4.4M
310.4K
Earning Date
05-26-2026
01-01-0001
Dividend Yield
5.05%
N/A
EPS Growth
4.84
N/A
EPS
5.42
N/A
Revenue
$22,386,892,000.00
N/A
Revenue This Year
$0.75
$40.84
Revenue Next Year
$5.36
$22.38
P/E Ratio
$15.65
$33.69
Revenue Growth
35.35
N/A
52 Week Low
$64.02
$510.06
52 Week High
$103.64
$934.62

Technical Indicators

Market Signals
Indicator
OKE
ARGX
Relative Strength Index (RSI) 57.13 32.21
Support Level $79.21 $698.92
Resistance Level $89.00 $856.67
Average True Range (ATR) 2.67 19.24
MACD -0.29 -6.24
Stochastic Oscillator 65.22 17.84

Price Performance

Historical Comparison
OKE
ARGX

About OKE ONEOK Inc.

Oneok is a diversified midstream service provider specializing in natural gas gathering, processing, storage, and transportation, as well as natural gas liquids transportation and fractionation. It also operates in the refined product and crude oil segment, connecting producers, refiners, and consumers. Operations are in the midcontinent, Permian, and Rocky Mountain regions.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: